Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • FROM THE ANALYST'S COUCH

Infectious disease vaccines

  1. Angela K. Shen

    1. Angela K. Shen is a retired captain from the United States Public Health Service. This work was performed when she was at the National Vaccine Program Office, Office of the Assistant Secretary for Health, US Department of Health and Human Services, Washington DC, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. M. Timothy Cooke

    1. M. Timothy Cooke is at Ology Bioservices, Alachua Florida, USA and the National Vaccine Advisory Committee, Washington DC, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Vaccines have a huge impact on human health in both industrialized and developing countries, but account for a small fraction of biopharmaceutical industry sales. Just 3.5% ($28 billion) of worldwide prescription drug sales were from vaccines in 2017, according to data from EvaluatePharma (Fig. 1; see Related links).

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 18, 169-170 (2019)

doi: https://doi.org/10.1038/d41573-018-00011-6

Acknowledgements

We are grateful to D. Thomas, C. Wessel and P. Arthur of the Biotechnology Innovation Organization for their critical review of the data, use of figures and their critical review of this manuscript.

Disclaimer

The opinions expressed in this manuscript are those of the authors and not intended to represent the opinions of the National Vaccine Program Office and the National Vaccine Advisory Committee.

Supplementary Information

  1. 41573_2019_CM16311542_MOESM1_ESM

Competing Interests

M.T.C. is an employee and shareholder of Ology Bioservices, and a board member, consultant and shareholder of NovaDigm Therapeutics. A.K.S. declares no competing interests.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links